T6054

GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380, 000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold selectivity against PDE4B versus PDE7.Phase 2.

Netivudine is a potent nucleoside reverse transcriptase inhibitor (NRTIs), a nucleoside analogue with anti-varicella zoster virus activity that can be used to treat human immunodeficiency virus (HIV) infection. Netivudine works by inhibiting reverse transcriptase, which reduces viral load in the body and slows the progression of the disease through its inhibitory effect.

BTK-IN-16 is a potential inhibitor of wild-type BTK and C481S mutants.BTK-IN-16 can be used to study various autoimmune diseases and cancers caused by BTK.

PCSK9 modulator-2 (Compound 1) is a potent PCSK9 modulator (EC 50 = 202 nM) with potential applications in hyperlipidemia research. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a recently validated therapeutic target for lowering low-density lipoprotein cholesterol (LDL-C) [1].

THK-523 has shown selectivity and high affinity for tau pathology both in vitro and in vivo. 18 F-THK523 is a potent tau imaging radiotracer which is a potent in vivo tau imaging ligand for Alzheimer's disease [1].

HPV18-IN-1 (Compound H1) is a potent HPV18 inhibitor that prevents premature cell progression and abnormal proliferation in cervical cancer cells. By suppressing the E7-Rb-E2F cellular pathway and DNA methylation, HPV18-IN-1 holds potential for cancer research.

Anti-MRSA agent 6 (compound 3q6) is a potent anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agent with low cytotoxicity for MCF-7 and A549 cells [1].

PF-06761281 (Compound 4a) is a potent and partially selective sodium-coupled citrate transporter protein (NaCT/SLC13A5) inhibitor with IC50 values of 0.51, 13.2, and 14.1 µM for NaCT, NaDC, and NaDC, respectively, and has the advantage of being orally active, reducing hepatic and renal uptake of citrate and plasma glucose concentration for metabolic diseases.

Guanoxabenz (Hydroxyguanabenz) hydrochloride is an α2 adrenergic receptor agonist with a Ki of 4000 nM and a fully activated form of 40 nM for the α2A adrenoceptor[1][2][3].